Zymeworks Stock
Zymeworks Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Kenneth H. Galbraith
- Employees
- 231
- Market cap
- $1.8 B
- IPO
- 28/04/2017
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase within the biotechnology industry. The company is dedicated to identifying, advancing, and bringing biological therapies aimed at combating cancer to the market. Its pipeline features two primary experimental treatments. One is zanidatamab, a…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Zymeworks stock: price history
1D
-2.8%
1W
-2.9%
1M
-4.6%
6M
-10.0%
YTD
-4.9%
1Y
+34.9%
2Y
+85.4%
5Y
-3.5%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~14% stronger price swings than usual
Ask the agents about Zymeworks
Analyst assessment of Zymeworks
PRICE TARGET LOW
US$32.00
CONSENSUS
US$41.40
MEDIAN
US$40.00
PRICE TARGET HIGH
US$55.00
0
STRONG BUY
20
BUY
2
HOLD
0
SELL
0
STRONG SELL
22
TOTAL · Buy
As of: 07/10/2026
Zymeworks stock metrics
P/E
-12.39
P/B
22.73
EV/EBITDA
-13.44
RETURN ON EQUITY
-56.0%
NET MARGIN
-980.8%
DEBT/EQUITY
3.34
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.0%
FLOAT SHARES
68,915,291
AVG. DAILY VOLUME (30D)
986,741
Insider transactions (SEC)
Schayowitz Adam
Schayowitz Adam
Hollywood Mark
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.8%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Zymeworks stock
What does Zymeworks do?
Zymeworks Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Kenneth H. Galbraith, the company employs around 231 people.
The IPO was on 28/04/2017; the stock trades on NASDAQ under the ticker ZYME.
What do analysts say about Zymeworks stock?
22 analysts rate the stock, the consensus is Buy (as of 07/10/2026).
The average price target is US$41.40, ranging from US$32.00 to US$55.00, with a median of US$40.00.
This is an external assessment, not a statement by Market Jury.
When does Zymeworks report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 14% stronger than usual.
Does Zymeworks pay a dividend?
No, Zymeworks currently does not pay a dividend.
Which stocks are comparable to Zymeworks?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Zymeworks stock analyzed?
Clicking "Analyze stock" lets five strategies assess Zymeworks against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.